Thrivent Financial for Lutherans Has $2.81 Million Stock Position in Becton, Dickinson and Company $BDX

Thrivent Financial for Lutherans reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 23.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 14,429 shares of the medical instruments supplier’s stock after selling 4,347 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Becton, Dickinson and Company were worth $2,805,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of BDX. Activest Wealth Management increased its position in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter worth about $25,000. Steph & Co. increased its position in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the last quarter. Cornerstone Planning Group LLC increased its position in Becton, Dickinson and Company by 463.3% in the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 139 shares during the last quarter. Finally, Accredited Wealth Management LLC increased its position in Becton, Dickinson and Company by 77.8% in the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BDX has been the topic of several research reports. TD Cowen dropped their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research report on Monday, May 4th. Stifel Nicolaus dropped their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. dropped their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Citigroup dropped their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Finally, Argus dropped their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $184.86.

Becton, Dickinson and Company Stock Performance

BDX opened at $147.76 on Monday. The company has a market cap of $40.71 billion, a PE ratio of 37.41, a price-to-earnings-growth ratio of 10.45 and a beta of 0.22. The stock has a 50-day moving average of $152.83 and a 200-day moving average of $178.08. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its stock is undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.